All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-05-16T10:18:49.000Z

iwCLL 2017 | Progression on ibrutinib in patients with somatic mutations in the BCR and NF-kB pathways 

Bookmark this article

The second session at this year’s iwCLL was titled “Role of Non-Leukemic Cells and the Microenvironment in CLL Development”, and was jointly chaired by Silvia Deaglio (University of Turin, Torino, Italy) and Christopher Pepper (Cardiff University, Wales, UK).

A talk titled “Progression on ibrutinib in patients with somatic mutations in the BCR and NF-kB pathways” was given during this session by Clare Sun from the National Institutes of Health, Bethesda, Maryland.

The presentation began with a summary slide detailing resistance mechanisms to ibrutinib:

Following this, a phase II trial was outlined assessing ibrutinib in patients with CLL or SLL who require treatment and are older than 65 years, have del(17p), or have TP53 mutation (NCT01500733):

  • Overall, 84 patients enrolled
  • Ibrutinib 420mg one daily until disease progression or intolerable side effects
  • PFS at 36 months = 83.6%
  • Higher risk of progression found in patients with del(17p)/mutated TP53, Rai stage III/IV, and R/R CLL
  • Targeted sequencing found mutations in BTK and/or PLCG2 in 9/13 (69%) patients
  • Mutations identified up to 15.4 months before clinical progression, but not at treatment initiation

Clare Sun then asked two key questions: are there mutations in the BCR and NF-kB pathways at baseline? Can such mutations predict clinical outcome during ibrutinib treatment?

Upon whole exome sequencing of patients on ibrutinib monotherapy:

N (range or %)

 

Current study

Entire cohort

Patients

45

84

Age

66 (33–85)

67 (33–85)

Male

27 (60%)

49 (58%)

Rai stage III/IV

28 (62%)

59 (70%)

Del(17p)

25 (56%)

52 (62%)

Previously treated

19 (42%)

32 (38%)

In total, 23 somatic mutations in BCR and/or members of the NF-kB pathway were identified in 17 patients: 17 missense mutations (13 “damaging”; PolyPhen-2), 4 frameshift indels, and 2 splice site mutations.

Association with baseline features:

Prognostic factor

BCR and/or NF-kB pathway mutations

P value

No

Yes

Del(17p)/mutated TP53

67.9%

58.8%

0.7

U-IGHV

60.7%

58.8%

1.0

R/R CLL

35.7%

52.9%

0.4

Clare Sun then moved the talk on to discuss oncogenic CARD11 mutations in ABC-DLBCL, which is dependent on NF-kB activations via BCR and MYD88 signaling pathways. Ibrutinib results in better ORR in ABC- than GCB-DLBCL. However, no response occurred in ABC-DLBCL patients with mutations in TNFAIP3 or CARD11 (Wilson et al. 2015).

The presentation was concluded with a succinct summary slide:

  1. Sun C. Progression on ibrutinib in patients with somatic mutations in the BCR and NF-kB pathways. XVII International Workshop on Chronic Lymphocytic Leukemia; 2017 May 12–15; New York, USA.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox